DNA 손상 반응 시장 : 업계 동향과 세계 예측 - 적응 질환별, 치료 영역별, 표적 분자별, 분자 유형별, 투여 경로별, 주요 지역별

GLOBAL DNA DAMAGE RESPONSE MARKET: OVERVIEW

As per Roots Analysis, the global DNA damage response market valued at USD 13 million in the current year is anticipated to grow at a lucrative CAGR during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Disease Indication

• Acute Myeloid Leukemias
• COVID-19
• Diabetic Macular Edemas
• Mesotheliomas
• Myelodysplastic Syndromes
• Non-Squamous Non-Small Cell Lung Cancers
• Prostate Cancers
• Uterine Serous Carcinomas

Therapeutic Area

• Hematological Malignancies
• Solid Tumors
• Other Disorders

Target Molecule

• APE1/Ref-1
• Casein Kinase 2
• CHK-1
• C-Tak
• DHODH
• MAPKAPK2
• p53
• WEE 1

Type of Molecule

• Biologics
• Small Molecule

Route of Administration

• Oral Drugs
• Intravenous Drugs

Key Geographical Regions

• North America (US and Canada)
• Europe (Denmark, France, Germany, Italy, Spain and UK)
• Asia-Pacific (Australia, Singapore and South Korea)

GLOBAL DNA DAMAGE RESPONSE MARKET: GROWTH AND TRENDS

The DNA damage response (DDR) consists of a coordinated network of pathways that not only facilitate the repair of DNA lesions but also activate cell cycle checkpoints. This leads to cell cycle arrest at critical stages in order to maintain the overall genomic integrity. Notably, if the damage is irreparable, this intricate system ensures that cells either repair their genetic material before undergoing division or facilitate programmed cell death to prevent the propagation of mutations. Further, its high specificity and sensitivity to conventional therapies, and low off-target toxicity have made DDR a promising therapeutic target for a broad range of clinical conditions, including both oncological and non-oncological diseases. Consequently, researchers worldwide are developing DDR inhibitors to counter DDR-mediated resistance to DNA-damaging anticancer therapies and to exploit DDR dysfunction in cancer by targeting alternative pathways.

It is worth mentioning that four poly-ADP ribose polymerase (PARP) inhibitor drugs, which target the DNA damage repair process, are currently approved for advanced-stage cancer treatment. Additionally, drug developers worldwide are investigating other molecular targets within the DNA damage response pathway, including ATM, ATR, CHK1, and WEE1.

GLOBAL DNA DAMAGE RESPONSE MARKET: KEY INSIGHTS

The report delves into the current state of global DNA damage response market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, close to 45 companies are engaged in the development of DNA damage response (DDR) targeting therapeutics in order to treat a range of clinical conditions.
• Majority of pipeline drug candidates are in the early phases of development; these are predominantly designed to target epitopes on biological molecules that are a characteristic of various oncological disorders.
• The preclinical pipeline of DDR targeting therapeutics is substantial and growing; majority of these drug candidates (over 75%) are small molecules.
• Over 70% of drug candidates targeting ATR are in clinical trials and around 55% of such interventions are designed for oral administration.
• About 65% of DDR targeting drugs intended to treat solid tumors have already demonstrated preclinical proof of concept.
• Since 2010, over 220 clinical trials have been registered to evaluate the efficacy of DDR targeting therapies; average completion time for such studies was relatively less in Asia-Pacific.

• Innovation in this field is evident across the plethora of scientific articles published in prestigious journals; the current focus appears to be on identification of novel targets, specifically against different types of cancers.
• The number of publications in this domain has increased significantly in the past one year; around 30% of the articles have been published since 2021.
• Published articles / papers indicate that the focus of current research activity is on target molecules, such as ATR, ADP, ATR and HSP.
• There has been an evident increase in research focused on DDR targeting therapies against cancers, such as leukemia, lung and ovarian cancers.
• Several parameters, ranging from initial stages of development to launch of the drug, influence the pricing and adoption rates; developers must consider the combination of all these factors to survive the competition.
• In pursuit of a competitive edge and the successful establishment of a large consumer base, it is imperative for innovators to understand both direct and indirect influences on the adoption and pricing of their respective products.
• Considering the promising development pipeline of therapies and encouraging clinical research outcomes, the DDR targeting therapeutics market is anticipated to grow at a significant annualized till 2035.
• The projected market opportunity is likely to be well-distributed across different target disease indications, routes of administration and key geographical regions.

Example Players in the DNA Damage Response Market

• Aprea Therapeutics
• AstraZeneca
• Chordia Therapeutics
• Mission Therapeutics
• Repare Therapeutics
• Senhwa Biosciences

GLOBAL DNA DAMAGE RESPONSE MARKET

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global DNA damage response market, focusing on key market segments, including [A] target disease indication, [B] therapeutic area, [C] target molecule, [D] type of molecule, [E] route of administration and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of DNA damage response targeting therapeutics, considering various parameters, such as [A] phase of development, [B] target disease indication(s), [C] therapeutic area, [D] target molecule, [E] type of molecule, [F] type of therapy, [G] dosage form, [H] route of administration and [I] special drug designation awarded (if any). Additionally, a comprehensive evaluation of the companies engaged in development of DNA damage response targeting therapeutics, based on [A] year of establishment, [B] company size (in terms of employee count) and [C] location of respective headquarters.
• Key Insights: An insightful analysis of contemporary market trends that have been depicted using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in DNA damage response market, [B] an analysis of DNA damage response targeting therapeutics developers, based on their target therapeutic area and company size, [C] a detailed analysis highlighting the regional distribution of developers engaged in DNA damage response market, and [D] a comprehensive analysis illustrating the distribution of DNA damage response targeting therapeutics.
• Company Profiles: In-depth profiles of companies engaged in the development of DNA damage response targeting therapeutics, focusing on [A] company overview, [B] details related to its respective drug candidates and [C] recent developments and an informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of more than 250 completed, ongoing and planned clinical studies of various DNA damage response targeting therapeutics, based on various relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] gender of patients enrolled, [D] trial phase, [E] recruitment status and study design, leading [F] sponsors / collaborators and leading players (in terms of number of trials conducted), [G] type of organization, [H] popular therapeutic areas and [I] regional distribution of trials.
• Publication Analysis: An insightful analysis of more than 150 peer-reviewed scientific articles related to DNA damage response targeting therapeutics, based on [A] year of publication, [B] type of publication, [C] key research hubs, [D] most popular authors, [E] provision of grant awarded, [F] target molecule, and [G] most popular journals.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of DNA Damage
• 3.3. DNA Damaging Agents
• 3.4. DNA Damage Response Systems
  • 3.4.1. Key Components of DNA Repair Pathways
• 3.5. Types of DNA Repair Pathways
  • 3.5.1. Direct Pathways
  • 3.5.2. Excision Repair Pathway
    • 3.5.2.1. Base Excision Repair Pathway
    • 3.5.2.2. Nucleotide Excision Repair Pathway
    • 3.5.2.3. Mismatch Repair Pathway
  • 3.5.3. Indirect Pathways
    • 3.5.3.1. Homologous Recombination (HR) Repair Pathway
    • 3.5.3.2. Non-homologous End Joining (NHEJ) Repair Pathway
• 3.6. Concluding Remarks

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. DNA Damage Response Targeting Therapeutics: Clinical Pipeline
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Target Disease Indication(s)
  • 4.2.3. Analysis by Therapeutic Area
  • 4.2.4. Analysis by Target Molecule
  • 4.2.5. Analysis by Type of Molecule
  • 4.2.6. Analysis by Type of Therapy
  • 4.2.7. Analysis by Dosage Form
  • 4.2.8. Analysis by Route of Administration
  • 4.2.9. Analysis by Special Drug Designation Awarded
• 4.3. DNA Damage Response Targeting Therapeutics: Preclinical Pipeline
  • 4.3.1. Analysis by Phase of Development
  • 4.3.2. Analysis by Target Disease Indication(s)
  • 4.3.3. Analysis by Therapeutic Area
  • 4.3.4. Analysis by Type of Molecule
  • 4.3.5. Analysis by Type of Therapy
• 4.4 DNA Damage Response Targeting Therapeutics: List of Developers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Location of Headquarters
  • 4.4.4. Leading Developers: Analysis by Number of Proprietary Product Candidates

5. KEY INSIGHTS

• 5.1. Chapter Overview
• 5.2. Analysis by Portfolio Strength, Phase of Development and Company Size (4D Bubble Chart)
• 5.3. Analysis by Therapeutic Area and Company Size (Treemap Representation)
• 5.4. Analysis by Location of Headquarters (World Map Representation)
• 5.5. Analysis by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration (Grid Representation)

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. Aprea Therapeutics
  • 6.2.1. Company Overview
  • 6.2.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.2.3. Recent Developments and Future Outlook
• 6.3. AstraZeneca
  • 6.3.1. Company Overview
  • 6.3.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.3.3. Recent Developments and Future Outlook
• 6.4. Chordia Therapeutics
  • 6.4.1. Company Overview
  • 6.4.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.4.3. Recent Developments and Future Outlook
• 6.5. Mission Therapeutics
  • 6.5.1. Company Overview
  • 6.5.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.5.3. Recent Developments and Future Outlook
• 6.6. Repare Therapeutics
  • 6.6.1. Company Overview
  • 6.6.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.6.3. Recent Developments and Future Outlook
• 6.7. Senhwa Biosciences
  • 6.7.1. Company Overview
  • 6.7.2. DNA Damage Response Targeting Therapeutics Portfolio
  • 6.7.3. Recent Developments and Future Outlook

7. CLINICAL TRIALS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Scope and Methodology
• 7.3. DNA Damage Response Targeting Therapeutics: Clinical Trial Analysis
  • 7.3.1. Analysis by Trial Registration Year
  • 7.3.2. Analysis by Number of Patients Enrolled
  • 7.3.3. Analysis by Gender of Patients Enrolled
  • 7.3.4. Analysis by Trial Phase
  • 7.3.5. Analysis by Recruitment Status
  • 7.3.6. Analysis by Study Design
  • 7.3.7. Analysis by Type of Sponsor / Collaborator
  • 7.3.8. Analysis by Therapeutic Area
  • 7.3.9. Reginal Analysis
  • 7.3.10. Case Study
  • 7.3.11. Most Active Industry Players: Analysis by Number of Clinical Trails
  • 7.3.12. Concluding Remarks

8. PUBLICATION ANALYSIS

• 8.1. Chapter Overview
• 8.2. Scope and Methodology
• 8.3. DNA Damage Response Targeting Therapeutics: List of Recent Publications
  • 8.3.1. Analysis by Year of Publication
  • 8.3.2. Analysis by Type of Publication
  • 8.3.3. Emerging Focus Areas
  • 8.3.4. Analysis by Key Research Journals
    • 8.3.4.1. Most Prominent Journals: Analysis by Number of Publications
    • 8.3.4.2. Analysis by Journal Impact Factor
    • 8.3.4.3. Most Prominent Journals: Analysis by Journal Impact Factor
  • 8.3.5. Analysis by Key Research Hubs
  • 8.3.6. Analysis by Target Molecule
    • 8.3.6.1. Most Popular Target Molecule: Analysis by Number of Publications
    • 8.3.6.2. Analysis by Year and Target Molecule
  • 8.3.7. Analysis by Grants Awarded
    • 8.3.7.1. Locations of Grant Awarding Organizations: Analysis by Number of Publications
  • 8.3.8. Publication Benchmarking Analysis

9. ANALYSIS OF KEY PARAMETERS IMPACTING DRUG PRICING AND ADOPTION

• 9.1. Chapter Overview
• 9.2. Key Market Drivers
• 9.3. Roots Analysis Framework
  • 9.3.1. Benchmarking Parameters
  • 9.3.2. Methodology
  • 9.3.3. Impact on Price and Adoption
  • 9.3.4. Impact on Pricing and Adoption of Individual Drugs / Drug Candidates
    • 9.3.4.1. Adavosertib
    • 9.3.4.2. APX3330
    • 9.3.4.3. ASLAN003
    • 9.3.4.4. CBP-501
    • 9.3.4.5. Eprenetapopt
    • 9.3.4.6. Irofulven
    • 9.3.4.7. LB-100
    • 9.3.4.8. Silmitasertib
    • 9.3.4.9. TRC-102
  • 9.3.5. Concluding Remarks

10. MARKET FORECAST

• 10.1. Chapter Overview
• 10.2. Scope and Limitations
• 10.3. Forecast Methodology and Key Assumptions
• 10.4. Global DNA Damage Response Targeting Therapeutics Market, Till 2035
  • 10.4.1. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication
    • 10.4.1.1. DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, Till 2035
    • 10.4.1.2. DNA Damage Response Targeting Therapeutics Market for COVID-19, Till 2035
    • 10.4.1.3. DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, Till 2035
    • 10.4.1.4. DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, Till 2035
    • 10.4.1.5. DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, Till 2035
    • 10.4.1.6. DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, Till 2035
    • 10.4.1.7. DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, Till 2035
    • 10.4.1.8. DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, Till 2035
  • 10.4.2. DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area
    • 10.4.2.1. DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, Till 2035
    • 10.4.2.2. DNA Damage Response Targeting Therapeutics Market for Solid Tumors, Till 2035
    • 10.4.2.3. DNA Damage Response Targeting Therapeutics Market for Other Disorders, Till 2035
  • 10.4.3. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule
    • 10.4.3.1. DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, Till 2035
    • 10.4.3.2. DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, Till 2035
    • 10.4.3.3. DNA Damage Response Targeting Therapeutics Market for CHK-1, Till 2035
    • 10.4.3.4. DNA Damage Response Targeting Therapeutics Market for C-Tak, Till 2035
    • 10.4.3.5. DNA Damage Response Targeting Therapeutics Market for DHODH, Till 2035
    • 10.4.3.6. DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, Till 2035
    • 10.4.3.7. DNA Damage Response Targeting Therapeutics Market for p53, Till 2035
    • 10.4.3.8. DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, Till 2035
    • 10.4.3.9. DNA Damage Response Targeting Therapeutics Market for WEE1, Till 2035
  • 10.4.4. DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule
    • 10.4.4.1. DNA Damage Response Targeting Therapeutics Market for Biologics, Till 2035
    • 10.4.4.2. DNA Damage Response Targeting Therapeutics Market for Small Molecules, Till 2035
  • 10.4.5. DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration
    • 10.4.5.1. DNA Damage Response Targeting Therapeutics Market for Oral Drugs, Till 2035
    • 10.4.5.2. DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, Till 2035
  • 10.4.6. DNA Damage Response Targeting Therapeutics Market: Distribution by Geography
    • 10.4.6.1. DNA Damage Response Targeting Therapeutics Market in the US, Till 2035
    • 10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Canada, Till 2035
    • 10.4.6.3. DNA Damage Response Targeting Therapeutics Market in Denmark, Till 2035
    • 10.4.6.4. DNA Damage Response Targeting Therapeutics Market in France, Till 2035
    • 10.4.6.5. DNA Damage Response Targeting Therapeutics Market in Germany, Till 2035
    • 10.4.6.6. DNA Damage Response Targeting Therapeutics Market in Italy, Till 2035
    • 10.4.6.7. DNA Damage Response Targeting Therapeutics Market in Spain, Till 2035
    • 10.4.6.8. DNA Damage Response Targeting Therapeutics Market in the UK, Till 2035
    • 10.4.6.9. DNA Damage Response Targeting Therapeutics Market in Australia, Till 2035
    • 10.4.6.10. DNA Damage Response Targeting Therapeutics Market in Singapore, Till 2035
    • 10.4.6.11. DNA Damage Response Targeting Therapeutics Market in South Korea, Till 2035
  • 10.4.7. Drug-wise Sales Forecast
    • 10.4.7.1 Adavosertib (AZD1775, MK-1775), AstraZeneca
      • 10.4.7.1.1. Target Patient Population
      • 10.4.7.1.2. Sales Forecast
      • 10.4.7.1.3. Net Present Value
      • 10.4.7.1.4. Value Creation Analysis
    • 10.4.7.2. APX3330, Apexian Pharmaceuticals
      • 10.4.7.2.1. Target Patient Population
      • 10.4.7.2.2. Sales Forecast
      • 10.4.7.2.3. Net Present Value
      • 10.4.7.2.4. Value Creation Analysis
    • 10.4.7.3. ASLAN003 (LAS 186323), Aslan Pharmaceuticals
      • 10.4.7.3.1. Target Patient Population
      • 10.4.7.3.2. Sales Forecast
      • 10.4.7.3.3. Net Present Value
      • 10.4.7.3.4. Value Creation Analysis
    • 10.4.7.4. CBP-501, CanBas
      • 10.4.7.4.1. Target Patient Population
      • 10.4.7.4.2. Sales Forecast
      • 10.4.7.4.3. Net Present Value
      • 10.4.7.4.4. Value Creation Analysis
    • 10.4.7.5. Eprenetapopt, Aprea Therapeutics
      • 10.4.7.5.1. Target Patient Population
      • 10.4.7.5.2. Sales Forecast
      • 10.4.7.5.3. Net Present Value
      • 10.4.7.5.4. Value Creation Analysis
    • 10.4.7.6. Irofulven, Allarity Therapeutics
      • 10.4.7.6.1. Target Patient Population
      • 10.4.7.6.2. Sales Forecast
      • 10.4.7.6.3. Net Present Value
      • 10.4.7.6.4. Value Creation Analysis
    • 10.4.7.7. LB-100 (Lixte Biotechnology)
      • 10.4.7.7.1. Target Patient Population
      • 10.4.7.7.2. Sales Forecast
      • 10.4.7.7.3. Net Present Value
      • 10.4.7.7.4. Value Creation Analysis
    • 10.4.7.8. Silmitasertib, Senhwa Biosciences
      • 10.4.7.8.1. Target Patient Population
      • 10.4.7.8.2. Sales Forecast
      • 10.4.7.8.3. Net Present Value
      • 10.4.7.8.4. Value Creation Analysis
  • 10.4.9 Concluding Remarks

11. CONCLUDING REMARKS

12. APPENDIX I: TABULATED DATA

13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION